Co-Authors
This is a "connection" page, showing publications co-authored by HEATH SKINNER and CURTIS R PICKERING.
Connection Strength
2.040
-
FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Cancer in a p53-Dependent Manner. Clin Cancer Res. 2024 01 05; 30(1):187-197.
Score: 0.245
-
p16 Represses DNA Damage Repair via a Novel Ubiquitin-Dependent Signaling Cascade. Cancer Res. 2022 03 01; 82(5):916-928.
Score: 0.216
-
Inhibition of histone acetyltransferase function radiosensitizes CREBBP/EP300 mutants via repression of homologous recombination, potentially targeting a gain of function. Nat Commun. 2021 11 03; 12(1):6340.
Score: 0.211
-
Caspase-8 loss radiosensitizes head and neck squamous cell carcinoma to SMAC mimetic-induced necroptosis. JCI Insight. 2020 12 03; 5(23).
Score: 0.198
-
Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints. Int J Radiat Biol. 2021; 97(8):1121-1128.
Score: 0.188
-
Variations in HPV function are associated with survival in squamous cell carcinoma. JCI Insight. 2019 Jan 10; 4(1).
Score: 0.173
-
Predicting Outcome in Head and Neck Cancer: miRNAs with Potentially Big Effects. Clin Cancer Res. 2019 03 01; 25(5):1441-1442.
Score: 0.171
-
Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clin Cancer Res. 2017 Jun 01; 23(11):2713-2722.
Score: 0.154
-
Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clin Cancer Res. 2016 Sep 15; 22(18):4643-50.
Score: 0.143
-
Down-regulation of malic enzyme 1 and 2: Sensitizing head and neck squamous cell carcinoma cells to therapy-induced senescence. Head Neck. 2016 04; 38 Suppl 1:E934-40.
Score: 0.136
-
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma. J Natl Cancer Inst. 2022 12 08; 114(12):1619-1627.
Score: 0.057
-
High enhancer activity is an epigenetic feature of HPV negative atypical head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022; 10:936168.
Score: 0.055
-
Evolutionary Action Score of TP53 Coding Variants Is Predictive of Platinum Response in Head and Neck Cancer Patients. Cancer Res. 2015 Apr 01; 75(7):1205-15.
Score: 0.033
-
Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer. Cancer Res. 2015 Apr 01; 75(7):1527-36.
Score: 0.033
-
Individualizing antimetabolic treatment strategies for head and neck squamous cell carcinoma based on TP53 mutational status. Cancer. 2012 Feb 01; 118(3):711-21.
Score: 0.026